• Shares of Alto Neuroscience (NYSE:ANRO) plunged 57% in post-market trading amid news that a Phase 2b study of the company’s drug ALTO-100 in the treatment of major depressive disorder, or MDD, failed to meet its primary endpoint.
• Alto (ANRO

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.